Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown. We randomly assigned participants in a 1:2:2:2:2 ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically ...

In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were ...

Revolutionary drug Lepodisiran dramatically lowers Lp(a) cholesterol, a major heart attack risk factor. Learn about this ...

Bien que son rôle exact reste inconnu, la lipoprotéine(a) — particule de LDL-cholestérol liée à une molécule proche du ...

Lepodisiran, an experimental drug by Eli Lilly, reduces the risk of genetic heart disease by 94%. The drug significantly decreases Lp(a) levels, a genetically inherited risk for heart attacks and ...

Though not yet available, lepodisiran could become a breakthrough treatment for a major cause of heart disease and stroke. An experimental drug seems to nearly eliminate a major—but often ...